Načítá se...
Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems
An ongoing need for new cancer therapeutics exists, especially ones that specifically home and target triple-negative breast cancer. Because triple-negative breast cancer express low or are devoid of estrogen, progesterone, or Her2/Neu receptors, another target must be used for advanced drug deliver...
Uloženo v:
| Vydáno v: | NPJ Precis Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5871908/ https://ncbi.nlm.nih.gov/pubmed/29872709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-017-0030-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|